- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Boehringer Ingelheim
|
One of the greatest challenges faced for ovarian cancer treatment and diagnosis is that less than 30% of all ovarian cancer cases are found at an early stage.1 |
||
 |
Stage 1 | |
|
In Stage 1, the tumour is limited to one or both ovaries. The tumour may be found on the ovarian surface. Of women diagnosed at stage 1, 82-92% will survive for 5 years or more.2 |
||
 |
Stage 2 |
|
| In Stage 2, the tumour invades one or both ovaries with extension into the pelvic region, but without spread to the abdomen. Of women diagnosed at stage 2, 51-69% will survive for 5 years or more.2 |
||
 |
Stage 3 | |
| In Stage 3, the tumour extends beyond the pelvis into the abdominal organs. Of women diagnosed at stage 3, 17-39% will survive for 5 years or more.2 |
||
| Stage 4 | ||
| In Stage 4, there is distant metastasis to the lung, liver, or lymph nodes in the neck. Of women diagnosed at stage 4, 11.5% will survive for 5 years or more.2 |
||
| If you want to find out more about ovarian cancer, please launch the animated infographic. | ||
|
1. Boyle P et al. World Cancer Report. International Agency for Research on Cancer 2008.
|
||
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
